# BridgeBio (BBIO) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/BBIO
## Company Profile
- Ticker: BBIO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 81.99 USD
- Market cap: 12511616138.960001 USD
- Last updated: 2026-08-05
## Business Overview
### Genetically Defined Diseases
BridgeBio Pharma develops medicines for genetic diseases and genetically driven cancers. Its decentralized portfolio model creates focused teams around individual disease programs.
### Attruby
Attruby, or acoramidis, is an oral transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy. It anchors BridgeBio's commercial rare-cardiovascular franchise.
### BBP-418
BBP-418 is an oral substrate-supplementation therapy under FDA review for limb-girdle muscular dystrophy type 2I/R9.
### Encaleret
Encaleret is an oral calcium-sensing-receptor antagonist being prepared for regulatory submission in autosomal dominant hypocalcemia type 1.
### Infigratinib
Low-dose oral infigratinib targets FGFR3 signaling in achondroplasia and is advancing toward an NDA based on late-stage clinical development.
## Why The Stock Is Moving

As of Aug 5, 2026, BBIO was little changed and closed at $81.99. No new same-company headline was identified in the current news window.

## Future Catalysts

- NDA submission for encaleret in autosomal dominant hypocalcemia type 1 in the first half of 2026.
- NDA submission for oral infigratinib in achondroplasia in the third quarter of 2026.
- FDA review milestones for the submitted BBP-418 application, including a potential Priority Review decision.

## Recent News
- 2026-08-03 11:30 EST — [BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET](https://biopharmsignal.com/news/BBIO/bridgebio-to-report-second-quarter-2026-financial-results-and-commercial-updates-0b329680) — Source: BridgeBio
- 2026-07-22 11:30 EST — [BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1](https://biopharmsignal.com/news/BBIO/bridgebio-announces-fda-acceptance-of-nda-for-encaleret-for-adh1-c90bb02f) — Source: BridgeBio
- 2026-07-10 20:01 EST — [BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-02809453) — Source: BridgeBio
- 2026-07-02 11:30 EST — [Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM](https://biopharmsignal.com/news/BBIO/acoramidis-associated-with-first-ever-early-and-sustained-direct-kidney-protecti-a72e923d) — Source: BridgeBio
- 2026-07-01 11:30 EST — [BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches](https://biopharmsignal.com/news/BBIO/bridgebio-raises-1-billion-in-preferred-equity-to-accelerate-present-and-upcomin-7cd369f3) — Source: BridgeBio